These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

453 related items for PubMed ID: 22660205

  • 1. The value of ¹⁸F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy.
    Myslivecek M, Neoral C, Vrba R, Vomackova K, Cincibuch J, Formanek R, Koranda P, Zapletalova J.
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun; 156(2):171-9. PubMed ID: 22660205
    [Abstract] [Full Text] [Related]

  • 2. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy.
    Kim MK, Ryu JS, Kim SB, Ahn JH, Kim SY, Park SI, Kim YH, Song HY, Shin JH, Jung HY, Lee GH, Choi KD, Cho KJ, Kim JH.
    Eur J Cancer; 2007 Jun; 43(9):1385-91. PubMed ID: 17512192
    [Abstract] [Full Text] [Related]

  • 3. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
    Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R, Komaki R, Macapinlac H, Munden RF, Putnam JB, Rice D, Smythe WR, Vaporciyan AA, Walsh GL, Wu TT, Roth JA.
    Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
    [Abstract] [Full Text] [Related]

  • 4. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
    Piessen G, Petyt G, Duhamel A, Mirabel X, Huglo D, Mariette C.
    Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
    [Abstract] [Full Text] [Related]

  • 5. Role of surgical resection in complete responders on FDG-PET after chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
    Jeong Y, Kim JH, Kim SB, Yoon DH, Park SI, Kim YH, Kim HR, Jung HY, Lee GH, Ryu JS.
    J Surg Oncol; 2014 Apr; 109(5):472-7. PubMed ID: 24301552
    [Abstract] [Full Text] [Related]

  • 6. Utility of 18F-FDG PET for Predicting Histopathologic Response in Esophageal Carcinoma following Chemoradiation.
    Arnett ALH, Merrell KW, Macintosh EM, James SE, Nathan MA, Shen KR, Ravi K, Neben Wittich MA, Haddock MG, Hallemeier CL.
    J Thorac Oncol; 2017 Jan; 12(1):121-128. PubMed ID: 27569732
    [Abstract] [Full Text] [Related]

  • 7. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
    Kukar M, Alnaji RM, Jabi F, Platz TA, Attwood K, Nava H, Ben-David K, Mattson D, Salerno K, Malhotra U, Kanehira K, Gannon J, Hochwald SN.
    JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
    [Abstract] [Full Text] [Related]

  • 8. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.
    Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, Cox JD, Komaki RR, Hong D, Lee HK, Putnam JB, Rice DC, Smythe WR, Thai L, Vaporciyan AA, Walsh GL, Wu TT, Roth JA.
    Cancer; 2004 Oct 15; 101(8):1776-85. PubMed ID: 15386332
    [Abstract] [Full Text] [Related]

  • 9. Prognostic value of metabolic response measured by 18F-FDG-PET in oesophageal cancer patients treated with definitive chemoradiotherapy.
    Onal C, Torun N, Guler OC, Yildirim BA.
    Nucl Med Commun; 2016 Dec 15; 37(12):1282-1289. PubMed ID: 27612030
    [Abstract] [Full Text] [Related]

  • 10. (18)F-FDG-PET/CT in assessing response to neoadjuvant chemoradiotherapy for potentially resectable locally advanced esophageal cancer.
    Metser U, Rashidi F, Moshonov H, Wong R, Knox J, Guindi M, Darling G.
    Ann Nucl Med; 2014 May 15; 28(4):295-303. PubMed ID: 24474598
    [Abstract] [Full Text] [Related]

  • 11. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer.
    Levine EA, Farmer MR, Clark P, Mishra G, Ho C, Geisinger KR, Melin SA, Lovato J, Oaks T, Blackstock AW.
    Ann Surg; 2006 Apr 15; 243(4):472-8. PubMed ID: 16552197
    [Abstract] [Full Text] [Related]

  • 12. Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer.
    Jayachandran P, Pai RK, Quon A, Graves E, Krakow TE, La T, Loo BW, Koong AC, Chang DT.
    Int J Radiat Oncol Biol Phys; 2012 Oct 01; 84(2):471-7. PubMed ID: 22381904
    [Abstract] [Full Text] [Related]

  • 13. FDG PET using SUVmax for preoperative T-staging of esophageal squamous cell carcinoma with and without neoadjuvant chemoradiotherapy.
    Huang YC, Lu HI, Huang SC, Hsu CC, Chiu NT, Wang YM, Chiu YC, Li SH.
    BMC Med Imaging; 2017 Jan 05; 17(1):1. PubMed ID: 28056868
    [Abstract] [Full Text] [Related]

  • 14. Detecting interval metastases and response assessment using 18F-FDG PET/CT after neoadjuvant chemoradiotherapy for esophageal cancer.
    Stiekema J, Vermeulen D, Vegt E, Voncken FE, Aleman BM, Sanders J, Boot H, van Sandick JW.
    Clin Nucl Med; 2014 Oct 05; 39(10):862-7. PubMed ID: 25140549
    [Abstract] [Full Text] [Related]

  • 15. Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy.
    Tan S, Kligerman S, Chen W, Lu M, Kim G, Feigenberg S, D'Souza WD, Suntharalingam M, Lu W.
    Int J Radiat Oncol Biol Phys; 2013 Apr 01; 85(5):1375-82. PubMed ID: 23219566
    [Abstract] [Full Text] [Related]

  • 16. Changes in Total Lesion Glycolysis Evaluated by Repeated F-18 FDG PET/CT as Prognostic Factor in Locally Advanced Esophageal Cancer Patients Treated with Preoperative Chemoradiotherapy.
    Chang S, Koo PJ, Kwak JJ, Kim SJ.
    Oncology; 2016 Apr 01; 90(2):97-102. PubMed ID: 26771676
    [Abstract] [Full Text] [Related]

  • 17. The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma.
    Klayton T, Li T, Yu JQ, Keller L, Cheng J, Cohen SJ, Meropol NJ, Scott W, Xu-Welliver M, Konski A.
    J Gastrointest Cancer; 2012 Dec 01; 43(4):612-8. PubMed ID: 22777832
    [Abstract] [Full Text] [Related]

  • 18. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
    van Heijl M, Omloo JM, van Berge Henegouwen MI, Hoekstra OS, Boellaard R, Bossuyt PM, Busch OR, Tilanus HW, Hulshof MC, van der Gaast A, Nieuwenhuijzen GA, Bonenkamp HJ, Plukker JT, Cuesta MA, Ten Kate FJ, Pruim J, van Dekken H, Bergman JJ, Sloof GW, van Lanschot JJ.
    Ann Surg; 2011 Jan 01; 253(1):56-63. PubMed ID: 21233607
    [Abstract] [Full Text] [Related]

  • 19. The role of sequential 18(F) -FDG PET/CT in predicting tumour response after preoperative chemoradiation for rectal cancer.
    Sun W, Xu J, Hu W, Zhang Z, Shen W.
    Colorectal Dis; 2013 May 01; 15(5):e231-8. PubMed ID: 23384167
    [Abstract] [Full Text] [Related]

  • 20. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
    Kauppi JT, Oksala N, Salo JA, Helin H, Karhumäki L, Kemppainen J, Sihvo EI, Räsänen JV.
    Acta Oncol; 2012 May 01; 51(5):636-44. PubMed ID: 22208782
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.